FDA.reportPublic FDA data

0.3 ML Comirnaty 2025-2026 0.0333 MG/ML Injection

RxCUI
2722614
RxNorm name
0.3 ML Comirnaty 2025-2026 0.0333 MG/ML Injection
Display name
0.3 ML Comirnaty 2025-2026 0.0333 MG/ML Injection
Full name
0.3 ML Comirnaty 2025-2026 0.0333 MG/ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:38:56

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
125742ComirnatyCOVID-19 Vaccine, mRNA351(a)Disc2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
48c86164-de07-4041-b9dc-f2b5744714e50.3 ML Comirnaty 2025-2026 0.0333 MG/ML InjectionSY20These highlights do not include all the information needed to use COMIRNATY safely and effectively. See full prescribing information for COMIRNATY. COMIRNATY ® (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202120260303
48c86164-de07-4041-b9dc-f2b5744714e5COMIRNATY 2025-2026 vaccine, 0.3 ML Injection, 5y to < 12yPSN20These highlights do not include all the information needed to use COMIRNATY safely and effectively. See full prescribing information for COMIRNATY. COMIRNATY ® (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202120260303
48c86164-de07-4041-b9dc-f2b5744714e5Comirnaty 2025-2026 vaccine, 0.3 ML Injection, 5y to < 12ySY20These highlights do not include all the information needed to use COMIRNATY safely and effectively. See full prescribing information for COMIRNATY. COMIRNATY ® (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202120260303
48c86164-de07-4041-b9dc-f2b5744714e50.3 ML SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 OMICRON (LP.8.1) 0.0333 MG/ML Injection [Comirnaty 2025-2026]SBD20These highlights do not include all the information needed to use COMIRNATY safely and effectively. See full prescribing information for COMIRNATY. COMIRNATY ® (COVID-19 Vaccine, mRNA) injectable suspension, for intramuscular use 2025-2026 Formula Initial U.S. Approval: 202120260303